Evaluation of AOC 1001's Therapeutic Potential in Myotonic Dystrophy Type 1 Patients.

Published Date: 16 Nov 2023

The chief medical officer of Avidity, Steve Hughes, MD, offered insight into the recently released positive phase 1/2 and OLE data assessing AOC 1001, an experimental antisense oligonucleotide, in individuals suffering from myotonic dystrophy type 1.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot